News Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 14:16:48 2026-01-21 EST			5-day change	1st Jan Change
4.335 ^USD	+2.48%		+3.83%	+20.22%

01-05	Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH	CI
01-05	Altimmune Says US FDA Grants Breakthrough Therapy Designation for Pemvidutide in MASH	MT

01-05	Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH	CI
01-05	Altimmune Says US FDA Grants Breakthrough Therapy Designation for Pemvidutide in MASH	MT
01-05	Altimmune receives FDA breakthrough therapy designation for pemvidutide in mash	RE
01-05	Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH	AQ
12-23	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
12-22	Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial	AQ
12-19	Altimmune, Inc. - Special Call
12-19	Altimmune, Inc. Announces Positive Topline Results from the Impact Phase 2B Mash Trial	CI
12-19	Altimmune Says Pemvidutide Showed "Significant" Improvements in MASH Patients at 48 Weeks	MT
12-19	Altimmune's liver disease drug shows benefits in study, but investors remain unimpressed	RE
12-19	Altimmune's drug for a type of liver disease shows benefits in mid-stage study	RE
12-19	Altimmune shares climb 6.9% premarket after positive trial data	RE
12-19	Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial	AQ
12-12	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
12-08	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
12-01	Altimmune, Inc. Announces CEO Changes	CI
12-01	Altimmune, Inc. Announces Executive Changes	CI
12-01	Altimmune CEO Vipin Garg to Step Down	MT
12-01	Altimmune announces CEO transition, succession plan	RE
12-01	Altimmune Announces CEO Transition and Succession Plan	AQ
11-26	Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference	AQ
11-25	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
11-20	Altimmune, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-20-2025 08:00 AM
11-12	Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting 2025	AQ
11-11	Presentation: A Phase 2, Multicenter, Randomized, Placebo-Controlled Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Filters